Niels Vande Casteele, Ph.D., is vice president of early clinical development and pharmacology at Mirador Therapeutics in San Diego, where he is responsible for the strategy, leadership and implementation of clinical development aspects across programs from preclinical through Phase II proof of concept. His responsibilities include providing strategic drug development input and clinical leadership to cross-functional teams and enabling operational excellence of development programs across the portfolio. In addition to his functional role, he serves as the project team lead for Mirador’s lead asset.
Vande Casteele has over a decade of experience in public-private research in the field of drug discovery and development for chronic immune-mediated diseases. He excels in leading strategic, scientific and medical aspects of clinical research and multicenter global clinical trials, with a focus on integration of clinical pharmacology and translational medicine principles to enable efficient early drug development.
Vande Casteele has a Bachelor of Pharmaceutical Sciences and a Master of Drug Design and Development, he is a doctor of pharmacy (PharmD) and he obtained his doctorate in pharmaceutical sciences focused on precision medicine from KU Leuven, Belgium. He has published over 140 peer-reviewed research articles and book chapters, given over 40 invited lectures globally and received awards for his research contributions from distinguished professional organizations in the United States and Europe. Vande Casteele has a faculty appointment as associate adjunct professor of medicine at UC San Diego, California, where he teaches a course on biologics and biosimilars drug development and mentors the next generation of pharmaceutical professionals.